CO020 | LEFT ATRIAL ENLARGEMENT AS A MARKER OF ADVERSE CLINICAL OUTCOMES: PRELIMINARY RESULTS OF A PROSPECTIVE COHORT STUDY
Abstract
Background and Aims. Left atrial enlargement (LAE) is a cardiac structural abnormality that signals adverse cardiovascular remodeling in response to chronic pressure and/or volume overload. LAE may be easily measured and graded with transthoracic echocardiography (TTE) using the left atrial volume index (LAVi), as suggested by current cardiac imaging guidelines, and has been linked to adverse cardiovascular outcomes. We have previously described a statistically significant association between LAE and 1-year cerebrovascular events in subjects without atrial fibrillation (AF) and ongoing anticoagulation. With this study, we aimed to assess the association between LAE and short-term all-cause mortality. Methods. We carried out a prospective cohort study across three teaching hospitals in Milan, Italy (Bassini, Niguarda, San Paolo), including consecutive adults undergoing TTE between 2012 and 2023. Patients with a history of AF or receiving anticoagulants (for any indication) were excluded from the analysis. LAE was categorized using the LAVi as absent (≤34 mL/m²), mild (>34 and ≤41 mL/m²), moderate (>41 and ≤48 mL/m²), or severe (>48 mL/m²). The primary outcome was all-cause mortality within 1 year of the index echocardiogram. Multivariate logistic regression models were used to evaluate the independent association of LAE with 1-year all-cause mortality. Results. We included 56,512 subjects with a median age of 67 years (47% female). Three thousand five hundred eighty-five subjects (6.3%) died within 1 year of the index TTE. In the multivariate analysis, all categories of LAE were associated with 1-year all-cause mortality compared with no LAE (mild: OR 1.5, 95% CI 1.4-1.7; moderate: OR 1.8, 95% CI 1.6-2.0; severe: OR 2.4, 95% CI 2.1-2.6). This association was independent of other clinically meaningful covariates, including age, diabetes mellitus, heart failure, left ventricular dysfunction, prior stroke, and cardioactive treatments (including antiplatelet agents and statins). The association between LAE and all-cause mortality was evident also across low-risk subgroups, such as subjects ≤65 years of age (mild LAE vs normal LAVi: 2.2, 95% CI 1.7-2.8; moderate LAE vs normal LAVi: 3.1, 95% CI 2.2-4.4; severe LAE vs normal LAVi: 4.4, 95% CI 3.3-5.9), with no hypertension (mild LAE vs normal LAVi: 2.4, 95% CI 2.0-2.8; moderate LAE vs normal LAVi: 4.0, 95% CI 3.3-4.8; severe LAE vs normal LAVi: 6.3, 95% CI 5.4-7.4) and with no diabetes (mild LAE vs normal LAVi: 2.2, 95% CI 2.0-2.4; moderate LAE vs normal LAVi: 3.1, 95% CI 2.7-3.6; severe LAE vs normal LAVi: 5.1, 95% CI 4.6-5.6). Conclusions. Our preliminary results suggest that, in subjects without AF and ongoing anticoagulation, LAE is significantly associated with short-term all-cause mortality. The increase in effect size with increasing degrees of LAE suggests the existence of a causal relationship between the two phenomena. The association between LAE and all-cause mortality was evident also in subjects nominally at low cardiovascular risk, suggesting that LAE may be an early indicator of frailty and poor prognosis in this subject population.
Related
- Safety and Preliminary Clinical Outcomes of Integrating Engineered Synthetic Lipid Vesicles (Biosomes) in a Skin Booster Protocol: A Prospective Observational Study
- Early Adverse Neonatal Outcomes Among Women With Diabetes in Pregnancy in Uganda: Incidence, Distribution and Associated Factors in a Multicenter Prospective Cohort Study
- Prospective evaluation assessing the influence of outcome definition, cohort inclusion and DORIS remission in predicting adverse pregnancy outcomes in women with systemic lupus erythematosus.
- Nutritional disorders have adverse effect on clinical outcomes and may increase healthcare costs following hip and knee arthroplasty—A systematic review
- Effects of rectal retractor use on dosimetric parameters, treatment-related adverse events, and clinical outcomes of cervical cancer brachytherapy: A retrospective tertiary-centre study
BibTeX
@article{clerici2026co020,
title = {{CO020 | LEFT ATRIAL ENLARGEMENT AS A MARKER OF ADVERSE CLINICAL OUTCOMES: PRELIMINARY RESULTS OF A PROSPECTIVE COHORT STUDY}},
author = {Bianca Clerici},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/722},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO020 | LEFT ATRIAL ENLARGEMENT AS A MARKER OF ADVERSE CLINICAL OUTCOMES: PRELIMINARY RESULTS OF A PROSPECTIVE COHORT STUDY
AU - Bianca Clerici
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/722
AB - Background and Aims. Left atrial enlargement (LAE) is a cardiac structural abnormality that signals adverse cardiovascular remodeling in response to chronic pressure and/or volume overload. LAE may be easily measured and graded with transthoracic echocardiography (TTE) using the left atrial volume index (LAVi), as suggested by current cardiac imaging guidelines, and has been linked to adverse cardiovascular outcomes. We have previously described a statistically significant association between LAE and 1-year cerebrovascular events in subjects without atrial fibrillation (AF) and ongoing anticoagulation. With this study, we aimed to assess the association between LAE and short-term all-cause mortality. Methods. We carried out a prospective cohort study across three teaching hospitals in Milan, Italy (Bassini, Niguarda, San Paolo), including consecutive adults undergoing TTE between 2012 and 2023. Patients with a history of AF or receiving anticoagulants (for any indication) were excluded from the analysis. LAE was categorized using the LAVi as absent (≤34 mL/m²), mild (>34 and ≤41 mL/m²), moderate (>41 and ≤48 mL/m²), or severe (>48 mL/m²). The primary outcome was all-cause mortality within 1 year of the index echocardiogram. Multivariate logistic regression models were used to evaluate the independent association of LAE with 1-year all-cause mortality. Results. We included 56,512 subjects with a median age of 67 years (47% female). Three thousand five hundred eighty-five subjects (6.3%) died within 1 year of the index TTE. In the multivariate analysis, all categories of LAE were associated with 1-year all-cause mortality compared with no LAE (mild: OR 1.5, 95% CI 1.4-1.7; moderate: OR 1.8, 95% CI 1.6-2.0; severe: OR 2.4, 95% CI 2.1-2.6). This association was independent of other clinically meaningful covariates, including age, diabetes mellitus, heart failure, left ventricular dysfunction, prior stroke, and cardioactive treatments (including antiplatelet agents and statins). The association between LAE and all-cause mortality was evident also across low-risk subgroups, such as subjects ≤65 years of age (mild LAE vs normal LAVi: 2.2, 95% CI 1.7-2.8; moderate LAE vs normal LAVi: 3.1, 95% CI 2.2-4.4; severe LAE vs normal LAVi: 4.4, 95% CI 3.3-5.9), with no hypertension (mild LAE vs normal LAVi: 2.4, 95% CI 2.0-2.8; moderate LAE vs normal LAVi: 4.0, 95% CI 3.3-4.8; severe LAE vs normal LAVi: 6.3, 95% CI 5.4-7.4) and with no diabetes (mild LAE vs normal LAVi: 2.2, 95% CI 2.0-2.4; moderate LAE vs normal LAVi: 3.1, 95% CI 2.7-3.6; severe LAE vs normal LAVi: 5.1, 95% CI 4.6-5.6). Conclusions. Our preliminary results suggest that, in subjects without AF and ongoing anticoagulation, LAE is significantly associated with short-term all-cause mortality. The increase in effect size with increasing degrees of LAE suggests the existence of a causal relationship between the two phenomena. The association between LAE and all-cause mortality was evident also in subjects nominally at low cardiovascular risk, suggesting that LAE may be an early indicator of frailty and poor prognosis in this subject population.
SN - 2785-5309
ER -